SMS Pharmaceuticals schedules 38th AGM for September 29 via video conference

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • SMS Pharmaceuticals schedules its 38th AGM for September 29, 2026
  • The meeting will be held via video conferencing without physical presence
  • Remote e-voting runs from September 25 to September 28, 2026
  • Record date for dividend eligibility is fixed at September 22, 2026
  • Book closure period extends from September 23 to September 29, 2026
powered bylight_fuzz_icon
50150730

*this image is generated using AI for illustrative purposes only.

SMS Pharmaceuticals has scheduled its 38th Annual General Meeting for Tuesday, September 29, 2026. The event will be conducted through Video Conferencing or Other Audio Visual Means, adhering to Ministry of Corporate Affairs and SEBI guidelines.

The meeting is set to begin at 10:30 am. Shareholders will transact ordinary and special business, including the approval of financial statements for the fiscal year ended March 31, 2026.

Voting and Record Dates

Remote e-voting facilities will be available from Friday, September 25, 2026, at 9:00 am until Monday, September 28, 2026, at 5:00 pm. Central Depository Services Limited (CDSL) has been appointed as the agency to facilitate electronic voting.

Key Date Detail
AGM Date September 29, 2026
E-voting Start September 25, 2026
E-voting End September 28, 2026
Record Date September 22, 2026
Book Closure September 23-29, 2026

Only members whose names appear in the Register of Members as of the cut-off date, September 22, 2026, are eligible to vote. The Register of Members and Share Transfer Books will remain closed from September 23 to September 29, 2026, inclusive.

Dividend Eligibility

The company has fixed September 22, 2026, as the record date for determining eligibility for dividends on equity shares, subject to approval at the AGM. Shareholders are advised to update their KYC and bank account details with their Depository Participants to ensure direct receipt of dividends.

Historical Stock Returns for SMS Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+4.90%+8.29%+7.96%+5.95%+67.86%+130.00%

What specific financial performance metrics or strategic initiatives will be highlighted in the FY2026 results presented at the AGM?

How might the proposed dividend payout ratio impact SMS Pharmaceuticals' future capital allocation and R&D investment plans?

Are there any special resolutions regarding executive compensation, board restructuring, or new share issuances scheduled for shareholder approval?

SMS Pharmaceuticals files FY26 BRSR report detailing sustainability metrics

scanx
Reviewed by
Jubin VScanX News Team
Key Highlights
  • SMS Pharmaceuticals filed its FY26 BRSR report with stock exchanges on September 4, 2026
  • Turnover reached ₹886.87 crore with exports contributing 66% of total revenue
  • Scope 1 emissions fell to 35,552.99 metric tonnes while Scope 2 rose to 62,026.13
  • Water withdrawal declined sharply to 219,939.60 kiloliters from 296,576.95 in FY25
  • Zero workplace fatalities and lost-time injuries recorded for the fiscal year
powered bylight_fuzz_icon
50050333

*this image is generated using AI for illustrative purposes only.

SMS Pharmaceuticals filed its Business Responsibility and Sustainability Report (BRSR) for FY26 with the BSE and NSE on September 4, 2026. The filing, mandated under Regulation 34(2)(f) of SEBI LODR Regulations, covers standalone operations for the period ending March 31, 2026. The company reported a turnover of ₹886.87 crore and net worth of ₹804.79 crore in the CSR section disclosures.

Operational and Workforce Data

The Hyderabad-based manufacturer operates three plants and one office nationally, serving markets across 20 Indian states and 45 countries. Exports contributed 66% to total turnover. The entity employs 1,266 permanent staff and 822 workers as of the fiscal year-end.

Employee turnover rates showed variation between categories. Permanent employee turnover stood at 18.16% in FY26, up from 15.26% in FY25. Permanent worker turnover rose to 21.07% from 8.99% in the prior year. Female representation among permanent employees was 6.56%, while the Board included one woman director (12.5%).

Employee Category Total Count Female Share Turnover Rate (FY26)
Permanent Employees 1,266 6.56% 18.16%
Permanent Workers 351 0% 21.07%
Non-Permanent Workers 471 12.10% N/A

Environmental and Safety Metrics

The company reported zero fatalities and zero lost-time injury frequency rates for both employees and workers in FY26. Total Scope 1 greenhouse gas emissions fell to 35,552.99 metric tonnes of CO2 equivalent from 37,300.11 in FY25. Scope 2 emissions rose to 62,026.13 from 52,416.47. Energy intensity per rupee of turnover decreased to 0.0000662028 from 0.0000719185.

Water withdrawal dropped significantly to 219,939.60 kiloliters from 296,576.95 in the previous year. The entity implemented Zero Liquid Discharge systems, reusing 52,664.52 KL of treated effluent. Total waste generated increased to 3,610.21 metric tonnes, driven largely by hazardous waste rising to 3,526.87 metric tonnes from 2,720.99.

Governance and CSR

No complaints were filed regarding sexual harassment, discrimination, or working conditions during the year. The company spent ₹79.80 lakh on CSR initiatives in Vizianagaram, Andhra Pradesh, and ₹10 lakh in Hyderabad, Telangana. Key initiatives included support for children with disabilities and open-heart surgery programs.

Historical Stock Returns for SMS Pharmaceuticals

1 Day5 Days1 Month6 Months1 Year5 Years
+4.90%+8.29%+7.96%+5.95%+67.86%+130.00%

How might the sharp increase in permanent worker turnover from 8.99% to 21.07% impact SMS Pharmaceuticals' production capacity and operational costs in FY27?

Given the rise in Scope 2 emissions despite lower energy intensity, what specific strategies is the company implementing to decarbonize its electricity supply in the coming fiscal year?

With hazardous waste generation increasing significantly to 3,526.87 metric tonnes, how does this trend align with the company's long-term sustainability goals and regulatory compliance risks?

More News on SMS Pharmaceuticals

1 Year Returns:+67.86%